KRASG12V/HLA-A*02:01-targeted chimeric antigen receptor T cells exhibit potent preclinical activity against solid tumors - PubMed
2 days ago
- #KRASG12V
- #solid tumors
- #CAR T cells
- CAR T cell therapy shows promise for solid tumors targeting KRASG12V/HLA-A*02:01 neoantigen.
- B9 CAR T cells demonstrated specific lysis of tumor cells and patient-derived organoids expressing the target.
- Preclinical studies showed effective tumor growth control in pancreatic ductal adenocarcinoma models.
- Safety assessments in mice revealed no detectable toxicity, supporting clinical applicability.
- Authors hold a patent for CAR T cell therapies for solid tumors, indicating potential commercial interest.